ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vonoprazan

Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.

Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.

Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 8, 201648 company-led studies, 2 open or runningNext primary completion: Oct 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only310 open or runningphase 4since Feb 8, 2016Sep 16, 2011none ahead
Phathom Pharmaceuticalsits history only142 open or runningphase 3since Oct 10, 2019Oct 10, 2019Oct 20, 2027phase 3 · NCT07752407
Genuine Research Center, Egyptits history only10 open or runningphase 1since Nov 14, 2021Nov 14, 2021none ahead
Hanlim Pharm.10 open or runningphase 1since Oct 14, 2024Oct 14, 2024none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 9, 2025Dec 9, 2025none ahead

Also a collaborator on its studies: Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2024First study: phase 1 study in Stomach UlcerFirst studyNCT06642987 · 30 enrolled · Korea, Republic of

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

The one study Hanlim Pharm. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06642987Stomach Ulcer · Korea, Republic of1CompletedNov 3, 202330

How it is read

Names in the registry

  • “TAK-438”, 32 entries
  • “Vonoprazan”, 20 entries
  • “Vonoprazan (Reference)”, 1 entry
  • “Vonoprazan Tablets”, 1 entry
  • “VOQUEZNA® Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.